EGFR and non-small cell lung carcinoma: Osimertinib is a third-generation EGFR tyrosine kinase inhibitor approved for metastatic EGFR-mutant non-small cell lung cancer [34], hence representing a possible option to treat PeCa in the second-line setting as a concept of drug repurposing.